Roth Capital Starts CRISPR Therapeutics (CRSP) at Buy

June 10, 2019 7:42 AM EDT Send to a Friend
Roth Capital initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login